Evan Loh
Chief Executive Officer chez PARATEK PHARMACEUTICALS, INC.
Fortune : 2 337 $ au 31/08/2023
Profil
Evan Loh is currently the Chief Executive Officer at Paratek Pharmaceuticals, Inc., an Independent Director at Eiger BioPharmaceuticals, Inc., and a Director at Adaptive Phage Therapeutics, Inc. Previously, he served as the Chairman & Chief Medical Officer at Paratek Pharmaceuticals, Inc. and Transcept Pharma, Inc. He was also the Chairman of the Antimicrobials Working Group.
Additionally, Dr. Loh held positions as an Independent Director at Windtree Therapeutics, Inc. and Nivalis Therapeutics, Inc. He worked as the Vice President-Clinical Research & Development at Wyeth LLC and as the Senior VP-Worldwide Research & Development at Pfizer Inc. He also held the position of Vice President-Multiple Therapeutic Areas at Wyeth Pharmaceuticals LLC.
Dr. Loh is a member of Harvard Medical School and Perelman School of Medicine.
He holds a doctorate degree from Harvard Medical School and an undergraduate degree from Harvard College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/11/2023 | 467 ( 0,03% ) | 2 337 $ | 31/03/2024 | |
| 21/09/2023 | 0 ( -.--% ) | - $ | 31/08/2023 |
Postes actifs de Evan Loh
| Sociétés | Poste | Début |
|---|---|---|
| PARATEK PHARMACEUTICALS, INC. | Chief Executive Officer | 25/06/2019 |
| EIGER BIOPHARMACEUTICALS, INC. | Director/Board Member | 18/09/2017 |
Adaptive Phage Therapeutics, Inc.
 Adaptive Phage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Adaptive Phage Therapeutics, Inc. provides therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company was founded by Gregory L. Merril and Carl R. Merril and is headquartered in Bethesda, MD. | Director/Board Member | 29/06/2021 |
Anciens postes connus de Evan Loh
| Sociétés | Poste | Fin |
|---|---|---|
| WINDTREE THERAPEUTICS, INC. | Director/Board Member | 07/06/2022 |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Director/Board Member | 01/07/2017 |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Chief Tech/Sci/R&D Officer | 01/10/2009 |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Chairman | - |
Formation de Evan Loh
| Harvard Medical School | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| WINDTREE THERAPEUTICS, INC. | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Paratek Pharmaceuticals, Inc. /Old/
 Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Adaptive Phage Therapeutics, Inc. provides therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company was founded by Gregory L. Merril and Carl R. Merril and is headquartered in Bethesda, MD. | Commercial Services |
Antimicrobials Working Group
 Antimicrobials Working Group Miscellaneous Commercial ServicesCommercial Services Antimicrobials Working Group is an American nonprofit company. The firm operates as an association of antimicrobials and diagnostics companies. The company says this about itself: AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of thirteen antimicrobials companies: Acurx Pharmaceuticals, Inc., Cidara Therapeutics Inc., CorMedix Inc., Crestone, Inc., Entasis Therapeutics Inc., Iterum Therapeutics Ltd., Melinta Therapeutics LLC, Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., Qpex Biopharma, Inc., SCYNEXIS Inc., UTILITY therapeutics Ltd., and Venatorx Pharmaceuticals, Inc. | Commercial Services |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
